logo
  

Adtran Q4 Profit Down - Quick Facts

Adtran Inc. (ADTN) reported that its net income for the fourth quarter 2014 declined to $9.29 million from $11.84 million in the fourth quarter of 2013. Earnings per share were $0.17 compared to $0.20 last year.

Non-GAAP earnings per share were $0.19 compared to $0.25 for the fourth quarter of 2013.

Quarterly sales declined to $143.98 million from $159.09 million in the previous year.

ADTRAN Chief Executive Officer Tom Stanton stated, "Our Company had a solid performance this quarter with most segments meeting or slightly exceeding our expectations. We continue to see positive trends as we enter 2015 and believe our geographic presence, market share gains and new product introductions position us well for the future."

Analysts polled by Thomson Reuters expected the company to report earnings of $0.07 per share and revenues of $141.62 million for the quarter. Analysts' estimates typically exclude special items.

The company also announced that its Board declared a cash dividend for the fourth quarter of 2014. The quarterly cash dividend is $0.09 per common share to be paid to holders of record at the close of business on February 5, 2015. The ex-dividend date is February 3, 2015 and the payment date is February 19, 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT